Jaguar Health reports Q2 EPS ($4.04) vs. ($41.35) last year

Reports Q2 revenue $2.7M vs. $2.7M last year. Lisa Conte, Jaguar’s president and CEO, said, “Our paramount near-term activities are our planned October 2024 commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S., progressing our rare disease development business, and our ongoing analysis of full data for the first and second 12-week stages of our pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea. As announced, we are collaborating with our clinical and scientific advisers to evaluate the significance of the clinically meaningful results identified in patients with breast and lung cancer in the initial data from OnTarget, as we plan to engage in discussions with the FDA to explore the possible pathway of approval to make crofelemer available to breast and lung cancer patients for CTD.”